Success Metrics

Clinical Success Rate

100.0%

Based on 2 completed trials

Completion Rate

100%(2/2)

Active Trials

1(25%)

Results Posted

0%(0 trials)

Phase Distribution

Ph phase_2

25%

Ph phase_1

75%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution4 total trials

Phase 1Safety & dosage

3(75.0%)

Phase 2Efficacy & side effects

1(25.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

100.0%

2 of 2 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(2)

Completed(2)

Detailed Status

Completed2

Not yet recruiting1

Recruiting1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

100.0%

Most Advanced

Phase 2

Trials by Phase

Phase 13 (75.0%)

Phase 21 (25.0%)

Trials by Status

completed250%

not_yet_recruiting125%

recruiting125%

Recent Activity

1 active trials

Showing 4 of 4

not_yet_recruitingphase_2

Phase 2 Trial of G207 + 5 Gy Radiation for Children With High-Grade Gliomas

NCT07649070

recruitingphase_1

HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors

NCT03911388

completedphase_1

HSV G207 Alone or With a Single Radiation Dose in Children With Progressive or Recurrent Supratentorial Brain Tumors

NCT02457845

completedphase_1

G207 Followed by Radiation Therapy in Malignant Glioma

NCT00157703

Clinical Trials (4)

Showing 4 of 4 trials

NCT07649070Phase 2

Phase 2 Trial of G207 + 5 Gy Radiation for Children With High-Grade Gliomas

Not Yet Recruiting

NCT03911388Phase 1

HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors

Recruiting

NCT02457845Phase 1

HSV G207 Alone or With a Single Radiation Dose in Children With Progressive or Recurrent Supratentorial Brain Tumors

Completed

NCT00157703Phase 1

G207 Followed by Radiation Therapy in Malignant Glioma

Completed

All 4 trials loaded

Drug Details

Intervention Type: BIOLOGICAL
Total Trials: 4